Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173471 | 0.92 | RAB9A (0.47) | HPGDALDH1A1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20173479 | 0.87 | MEN1 (0.33) | ALDH1A1SMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL20163535 | 0.87 | MEN1 (0.33) | ALDH1A1SMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL20163534 | 0.87 | MEN1 (0.33) | ALDH1A1SMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL20163458 | 0.86 | HRH3 (0.41) | HPGDALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20163454 | 0.86 | HRH3 (0.41) | HPGDALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20173481 | 0.85 | GPR183 (0.33) | ALDH1A1SMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL18261099 | 0.84 | PDE1A (0.38) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18260871 | 0.84 | PDE1A (0.38) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18260869 | 0.84 | PDE1A (0.38) | ALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | HPGD 3422/4885ALDH1A1 1046/4885SMN1; SMN2 1207/4885 |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | BRCA1, ESR2, ESR1 | HPGD 2899/4885ALDH1A1 608/4885SMN1; SMN2 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.